Outcome after surgical treatment of endocrine pancreatic tumors

S. Fukuyama, S. Matsuno, S. Egawa, M. Sunamura

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Citation (Scopus)


Pancreatic endocrine tumors constitute a wide variety of rare lesions that are named according to the hormones that they produce. The most common pancreatic islet cell tumors are insulinoma and gastrinoma, followed in frequency of diagnosis by glucagonomas and vasoactive intestinal peptide (VIP)omas. Somatostatinomas are even more unusual. Nonfunctioning neoplasms with morphological features of islet cell tumors constitute 30% of pancreatic islet cell tumors [1]. According to a report from Japan Pancreas Society (JPS) [2], of 11,819 epithelial tumors, 307 cases were with endocrine tumors and the cumulative 5-year survival of the patients after pancreatectomy for islet cell tumor in Japan is 74.3%, while that of the patients with nonfunctioning islet cell tumor is 50%. The 5-year survival of the patients of stage IVa and IVb (of JPS) were 62.1% and 39.4% and was significantly lower than that of patients disease of other stages (Fig. 66.1). We describe herein details of the surgical outcome of endocrine tumors of pancreas.

Original languageEnglish
Title of host publicationDiseases of the Pancreas
Subtitle of host publicationCurrent Surgical Therapy
PublisherSpringer Berlin Heidelberg
Number of pages4
ISBN (Print)9783540286554
Publication statusPublished - 2008


Dive into the research topics of 'Outcome after surgical treatment of endocrine pancreatic tumors'. Together they form a unique fingerprint.

Cite this